다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Current pharmaceutical design, v.27 no.13, 2021년, pp.1549 - 1552
Torabi-Rahvar, Monireh (Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran,Iran) , Rezaei, Nima (Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran,Iran)
AI-Helper
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may lead to severe disease in some cases, leading to acute respiratory distress syndrome, multi-organ failure, and death. This severe phenotype seems to be associated with a cytokine storm and immune dysregulation. Increased pro-inflammato...
Nat Rev Immunol Cao X. 20 269 2020 10.1038/s41577-020-0308-3 Cao X.; COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 2020,20(5),269-270
Lancet Rheumatol Mehta P. 2 e358 2020 10.1016/S2665-9913(20)30096-5 Mehta P.; Cron R.Q.; Hartwell J.; Manson J.J.; Tattersall R.S.; Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol 2020,2(6),e358-e367
EBioMedicine Liu J. 55 2020 10.1016/j.ebiom.2020.102763 Liu J.; Li S.; Liu J.; Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020,55
Life Sci Yazdanpanah F. 256 2020 10.1016/j.lfs.2020.117900 Yazdanpanah F.; Hamblin M.R.; Rezaei N.; The immune system and COVID-19: Friend or foe? Life Sci 2020,256
Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19 medRxiv Zhang B 7 157 2020 Zhang B; Zhou X; Zhu C; Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19 medRxiv 2020,7,157
J Clin Invest Chen G. 130 2620 2020 10.1172/JCI137244 Chen G.; Wu D.; Guo W.; Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020,130(5),2620-2629
Lancet Respir Med Xu Z. 8 420 2020 10.1016/S2213-2600(20)30076-X Xu Z.; Shi L.; Wang Y.; Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020,8(4),420-422
Cell Biol Int Fathi N. 44 1792 2020 10.1002/cbin.11403 Fathi N.; Rezaei N.; Lymphopenia in COVID-19: Therapeutic opportunities. Cell Biol Int 2020,44(9),1792-1797
Natl Sci Rev Zhou Y 2020 10.1093/nsr/nwaa041 Zhou Y; Fu B; Zheng X; Wang D; Zhao C.; Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev 2020
medRxiv Liao M 2020 Liao M; Liu Y; Yuan J; The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. medRxiv 2020
Clin Infect Dis Qin C. 71 762 2020 10.1093/cid/ciaa248 Qin C.; Zhou L.; Hu Z.; Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020,71(15),762-768
Lancet Huang C. 395 497 2020 10.1016/S0140-6736(20)30183-5 Huang C.; Wang Y.; Li X.; Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020,395(10223),497-506
J Med Virol Lotfi M. 92 1864 2020 10.1002/jmv.26123 Lotfi M.; Rezaei N.; SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences. J Med Virol 2020,92(10),1864-1874
Immunity Vabret N. 52 910 2020 10.1016/j.immuni.2020.05.002 Vabret N.; Britton G.J.; Gruber C.; Immunology of COVID-19: current state of the science. Immunity 2020,52(6),910-941
Hellenic J Cardiol Deftereos S.G. 61 42 2020 10.1016/j.hjc.2020.03.002 Deftereos S.G.; Siasos G.; Giannopoulos G.; The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design. Hellenic J Cardiol 2020,61(1),42-45
Nature Gordon D.E. 583 459 2020 10.1038/s41586-020-2286-9 Gordon D.E.; Jang G.M.; Bouhaddou M.; A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020,583(7816),459-468
J Microbiol Immunol Infect Wu D. 53 368 2020 10.1016/j.jmii.2020.03.005 Wu D.; Yang X.O.; TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect 2020,53(3),368-370
Interaction of SARS and MERS coronaviruses with the antiviral interferon response Advances in virus research 96 Kindler E. 219 2016 Kindler E.; Thiel V.; Weber F.; Interaction of SARS and MERS coronaviruses with the antiviral interferon response Advances in virus research 96 2016,219-243
Nat Rev Microbiol de Wit E. 14 523 2016 10.1038/nrmicro.2016.81 de Wit E.; van Doremalen N.; Falzarano D.; Munster V.J.; SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016,14(8),523-534
Clin Chim Acta Lotfi M. 508 254 2020 10.1016/j.cca.2020.05.044 Lotfi M.; Hamblin M.R.; Rezaei N.; COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta 2020,508,254-266
Am J Respir Crit Care Med Brun-Buisson C. 183 1200 2011 10.1164/rccm.201101-0135OC Brun-Buisson C.; Richard J-C.M.; Mercat A.; Thiébaut A.C.; Brochard L.; Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011,183(9),1200-1206
Nat Rev Drug Discov Zumla A. 15 327 2016 10.1038/nrd.2015.37 Zumla A.; Chan J.F.; Azhar E.I.; Hui D.S.; Yuen K-Y.; Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016,15(5),327-347
Leukemia Li H. 34 1503 2020 10.1038/s41375-020-0848-3 Li H.; Chen C.; Hu F.; Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia 2020,34(6),1503-1511
J Infect Yang Z. 81 e13 2020 10.1016/j.jinf.2020.03.062 Yang Z.; Liu J.; Zhou Y.; Zhao X.; Zhao Q.; Liu J.; The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect 2020,81(1),e13-e20
Mil Med Res Jin Y-H. 7 4 2020 10.1186/s40779-020-0233-6 Jin Y-H.; Cai L.; Cheng Z-S.; A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020,7(1),4
JAMA Intern Med Wu C. 180 934 2020 10.1001/jamainternmed.2020.0994 Wu C.; Chen X.; Cai Y.; Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020,180(7),934-943
Lancet Russell C.D. 395 473 2020 10.1016/S0140-6736(20)30317-2 Russell C.D.; Millar J.E.; Baillie J.K.; Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020,395(10223),473-475
Signal Transduct Target Ther Zhou W. 5 18 2020 10.1038/s41392-020-0127-9 Zhou W.; Liu Y.; Tian D.; Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther 2020,5(1),18
Signal Transduct Target Ther Wang Y. 5 57 2020 10.1038/s41392-020-0158-2 Wang Y.; Jiang W.; He Q.; A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther 2020,5(1),57
Emerg Microbes Infect Han H. 9 1123 2020 10.1080/22221751.2020.1770129 Han H.; Ma Q.; Li C.; Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect 2020,9(1),1123-1130
Blood Adv Zhang X. 4 1307 2020 10.1182/bloodadvances.2020001907 Zhang X.; Song K.; Tong F.; First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv 2020,4(7),1307-1310
Ann Oncol Michot J-M. 31 961 2020 10.1016/j.annonc.2020.03.300 Michot J-M.; Albiges L.; Chaput N.; Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol 2020,31(7),961-964
J Med Virol Luo P. 92 814 2020 10.1002/jmv.25801 Luo P.; Liu Y.; Qiu L.; Liu X.; Liu D.; Li J.; Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 2020,92(7),814-818
J Transl Med Fu B. 18 164 2020 10.1186/s12967-020-02339-3 Fu B.; Xu X.; Wei H.; Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med 2020,18(1),164
Int J Antimicrob Agents Zhao M. 55 2020 10.1016/j.ijantimicag.2020.105982 Zhao M.; Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents 2020,55(6)
Crit Care Med Shakoory B. 44 275 2016 10.1097/CCM.0000000000001402 Shakoory B.; Carcillo J.A.; Chatham W.W.; Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior Phase III trial. Crit Care Med 2016,44(2),275-281
Rheumatology (Oxford) Miettunen P.M. 50 417 2011 10.1093/rheumatology/keq218 Miettunen P.M.; Narendran A.; Jayanthan A.; Behrens E.M.; Cron R.Q.; Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011,50(2),417-419
Nat Rev Immunol Risitano A.M. 23 1 2020 Risitano A.M.; Mastellos D.C.; Huber-Lang M.; Complement as a target in COVID-19? Nat Rev Immunol 2020,23,1-2
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.